Celera Genomics And Specialty Laboratories Announce Licensing Agreement For Commercialization Of Cirrhosis Testing

ROCKVILLE, Md. & VALENCIA, Calif.--(BUSINESS WIRE)--June 22, 2006--Celera Genomics (NYSE:CRA - News), an Applera Corporation business, and Specialty Laboratories today announced that they have signed an agreement granting Specialty a non-exclusive license to Celera's risk markers for cirrhosis. The license agreement allows Specialty to select from among Celera's genetic findings to develop and commercialize a genetic test that predicts risk of progression to liver cirrhosis in individuals infected with hepatitis C virus (HCV).